48,696 Novo Nordisk A/S $NVO Shares Sold by Carnegie Investment Counsel

Key Points

• Carnegie Investment Counsel cut its Novo Nordisk stake by 28.6% in the third quarter, selling 48,696 shares and retaining 121,560 shares valued at approximately $4.6 million.
• Analyst sentiment is mixed but leans toward caution: Novo Nordisk has an average “Hold” rating and a consensus price target of $59.44, while several firms recently issued or reiterated “Sell” ratings.
• Novo’s CagriSema obesity treatment showed a 25% average weight reduction in a late-stage analysis, offering potential growth support, but competition, pricing pressure, regulatory risks, and declining earnings estimates continue to weigh on the stock.

Carnegie Investment Counsel lowered its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 28.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,560 shares of the company's stock after selling 48,696 shares during the quarter. Carnegie Investment Counsel's holdings in Novo Nordisk A/S were worth $4,608,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Scarborough Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $26,000. Continuum Advisory LLC acquired a new position in shares of Novo Nordisk A/S in the second quarter worth about $38,000. Markowski Investments acquired a new position in shares of Novo Nordisk A/S in the second quarter worth about $43,000. Cassaday & Co Wealth Management LLC purchased a new position in Novo Nordisk A/S in the first quarter valued at about $45,000. Finally, Philadelphia Investment Partners LLC purchased a new position in Novo Nordisk A/S in the second quarter valued at about $71,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Citigroup restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Friday, October 9th. Cfra lowered Novo Nordisk A/S from a "hold" rating to a "sell" rating and set a $38.00 target price on the stock. in a research report on Tuesday, September 22nd. Weiss Ratings lowered Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, October 8th. HSBC reiterated a "hold" rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Finally, Deutsche Bank Aktiengesellschaft reissued a "sell" rating on shares of Novo Nordisk A/S in a research report on Tuesday, September 29th. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus target price of $59.44.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced an average 25% reduction in body weight after 68 weeks among women with obesity or overweight in a late-stage analysis. The result strengthens the drug’s potential as a successor to Wegovy and could improve Novo’s long-term position in the expanding obesity-treatment market. Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
• Positive Sentiment: The CagriSema data prompted a recent rally as investors viewed the treatment’s efficacy as a potential catalyst for renewed growth. Regulatory submissions and further clinical progress could provide additional upside, although approval is not yet guaranteed. Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
• Positive Sentiment: Novo expanded its 2026 share buyback, increasing its treasury-share stake to 1.2%. The program signals management’s confidence and may support earnings per share by reducing the number of shares outstanding. Novo Nordisk expands 2026 share buyback
• Neutral Sentiment: Novo remains a major player in diabetes and obesity treatments, with additional pipeline projects and partnerships offering potential growth over the next decade. However, those benefits depend on successful trials, regulatory approvals, manufacturing investment, and commercialization. Where Will Novo Stock Be in 10 Years?
• Negative Sentiment: Investors continue to assess rising competition from Eli Lilly and Viking Therapeutics, along with risks from drug-pricing pressure, intellectual-property challenges, and declining earnings estimates. These concerns help explain why the stock remains under pressure despite the promising CagriSema results. How Investors May Respond To Novo Nordisk Obesity Drug Competition

Novo Nordisk A/S Price Performance

NVO opened at $39.10 on Thursday. The company has a market capitalization of $174.58 billion, a P/E ratio of 9.56, a PEG ratio of 1.34 and a beta of 0.76. The company has a 50-day moving average of $42.21 and a 200-day moving average of $44.01. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. Equities analysts expect that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were paid a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This is a decrease from Novo Nordisk A/S's previous dividend of $1.2751. This represents a yield of 258.0%. Novo Nordisk A/S's payout ratio is currently 20.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.